WO2004062559A3 - Use of microcapsules comprising an antigen for the manufacture of an ex-vivo medicament to initiate an immune response - Google Patents

Use of microcapsules comprising an antigen for the manufacture of an ex-vivo medicament to initiate an immune response Download PDF

Info

Publication number
WO2004062559A3
WO2004062559A3 PCT/GB2004/000114 GB2004000114W WO2004062559A3 WO 2004062559 A3 WO2004062559 A3 WO 2004062559A3 GB 2004000114 W GB2004000114 W GB 2004000114W WO 2004062559 A3 WO2004062559 A3 WO 2004062559A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
immune response
microcapsules
initiate
manufacture
Prior art date
Application number
PCT/GB2004/000114
Other languages
French (fr)
Other versions
WO2004062559A2 (en
Inventor
Angie Westwood
Gareth David Healey
James Edward Eyles
Ethel Diane Williamson
Original Assignee
Secr Defence
Angie Westwood
Gareth David Healey
James Edward Eyles
Ethel Diane Williamson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Secr Defence, Angie Westwood, Gareth David Healey, James Edward Eyles, Ethel Diane Williamson filed Critical Secr Defence
Publication of WO2004062559A2 publication Critical patent/WO2004062559A2/en
Publication of WO2004062559A3 publication Critical patent/WO2004062559A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/464819—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis

Abstract

The use of a microcapsule comprising an antigen in the preparation of a medicament for administration to an antigen-presenting cell such as a dendritic cell of a patient, for the activation of the immune response of said patient. APC treated using the microcapsule may be used in prophylaxis or therapy, for example to protect a patient against infection by a pathogen.
PCT/GB2004/000114 2003-01-15 2004-01-14 Use of microcapsules comprising an antigen for the manufacture of an ex-vivo medicament to initiate an immune response WO2004062559A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0300881.0A GB0300881D0 (en) 2003-01-15 2003-01-15 Therapeutic treatment
GB0300881.0 2003-01-15

Publications (2)

Publication Number Publication Date
WO2004062559A2 WO2004062559A2 (en) 2004-07-29
WO2004062559A3 true WO2004062559A3 (en) 2004-09-02

Family

ID=9951177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/000114 WO2004062559A2 (en) 2003-01-15 2004-01-14 Use of microcapsules comprising an antigen for the manufacture of an ex-vivo medicament to initiate an immune response

Country Status (2)

Country Link
GB (1) GB0300881D0 (en)
WO (1) WO2004062559A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0266119A2 (en) * 1986-10-24 1988-05-04 Southern Research Institute Method and formulation for orally administering bioactive agents to and through the Peyer's patch
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
WO2001070200A1 (en) * 2000-03-22 2001-09-27 The Secretary Of State For Defence Pharmaceutical composition for administration to mucosal surfaces
US20010031262A1 (en) * 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
WO2002015877A2 (en) * 2000-08-23 2002-02-28 Alkermes Controlled Therapeutics, Inc. Methods and compositions for targeted delivery
US20020136776A1 (en) * 2000-09-28 2002-09-26 Jia-Hwa Fang Microparticle compositions and methods for the manufacture thereof
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0266119A2 (en) * 1986-10-24 1988-05-04 Southern Research Institute Method and formulation for orally administering bioactive agents to and through the Peyer's patch
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US20010031262A1 (en) * 1999-12-06 2001-10-18 Michael Caplan Controlled delivery of antigens
WO2001070200A1 (en) * 2000-03-22 2001-09-27 The Secretary Of State For Defence Pharmaceutical composition for administration to mucosal surfaces
WO2002015877A2 (en) * 2000-08-23 2002-02-28 Alkermes Controlled Therapeutics, Inc. Methods and compositions for targeted delivery
US20020136776A1 (en) * 2000-09-28 2002-09-26 Jia-Hwa Fang Microparticle compositions and methods for the manufacture thereof
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2003 (2003-03-01), SAMUEL JOHN: "PLGA nanosphere delivery of peptides and lipopeptides to dendritic cells.", XP008031909 *
EYLES J E ET AL: "Protection studies following bronchopulmonary and intramuscular immunisation with Yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 18, no. 28, August 2000 (2000-08-01), pages 3266 - 3271, XP004205869, ISSN: 0264-410X *
JOHANSEN P ET AL: "Ambiguities in the preclinical quality assessment of microparticulate vaccines", TRENDS IN BIOTECHNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 18, no. 5, May 2000 (2000-05-01), pages 203 - 211, XP004196001, ISSN: 0167-7799 *

Also Published As

Publication number Publication date
GB0300881D0 (en) 2003-02-12
WO2004062559A2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
WO2006085983A3 (en) Viral adjuvants
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
WO2004000209A3 (en) Administration of therapeutic viruses
AR032912A1 (en) PHARMACEUTICAL FORMULATION
WO2005084306A3 (en) Immunogenic compositions for chlamydia pneunomiae
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
WO2003059385A3 (en) Hiv vaccine and method of use
WO2002087494A3 (en) Novel vaccine
ITMI20031617A1 (en) MICROCAPSULE WITH DOUBLE LAYER OF USE POLISACCHARIDES
WO2003041735A3 (en) Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system
WO2004030696A3 (en) Composition for vaccination
AU2002347671A1 (en) Ophthalmic device for administering fluid eye medication to the human eye
WO2007110709A8 (en) Formulations of tipifarnib for intravenous administration
AU2003260426A1 (en) Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
WO2003039592A3 (en) Cellular vaccines comprising adjuvants
WO2002053149A3 (en) Medicament containing a polyamine as an active substance
WO2004062559A3 (en) Use of microcapsules comprising an antigen for the manufacture of an ex-vivo medicament to initiate an immune response
WO2002053176A3 (en) An autologous anti-cancer vaccine
WO2003080112A3 (en) Imidazoquinolineamines as adjuvants in hiv dna vaccination
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
WO2003032917A3 (en) Hookworm vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)